Who are Bio-three's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Probiotic Supplement, Probiotic : Saccharomyces boulardii, Probiotics(VSL#3), Mixture of three Bifidobacteria, Ganeden BC30, Pro-biotics.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bio-three.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Bio-three — Competitive Intelligence Brief

Bio-three (Bio-three) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Probiotic. Area: Gastroenterology.

marketed Probiotic Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

Bio-three (Bio-three) — Kaohsiung Veterans General Hospital.. Bio-three is a probiotic formulation containing multiple beneficial bacterial strains that restore and maintain healthy gut microbiota.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
Bio-three TARGET	Bio-three	Kaohsiung Veterans General Hospital.	marketed	Probiotic
Probiotic Supplement	Probiotic Supplement	Sheppard Pratt Health System	marketed	Probiotic supplement
Probiotic : Saccharomyces boulardii	Probiotic : Saccharomyces boulardii	Biocodex	marketed	Probiotic
Probiotics(VSL#3)	Probiotics(VSL#3)	Govind Ballabh Pant Hospital	marketed	Probiotic
Mixture of three Bifidobacteria	Mixture of three Bifidobacteria	Federico II University	marketed	Probiotic
Ganeden BC30	Ganeden BC30	Massachusetts General Hospital	marketed	Probiotic
Pro-biotics	Pro-biotics	National Cheng-Kung University Hospital	marketed	Probiotic

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Probiotic class)

BioBalance Corporation · 1 drug in this class
Biocodex · 1 drug in this class
CD Pharma India Pvt. Ltd. · 1 drug in this class
CHU de Quebec-Universite Laval · 1 drug in this class
Chuncheon Sacred Heart Hospital · 1 drug in this class
Dow University of Health Sciences · 1 drug in this class
Federico II University · 1 drug in this class
Fundación Hospital de Pediatría Prof. Dr. Juan P. Garrahan · 1 drug in this class
GWT-TUD GmbH · 1 drug in this class
Aga Khan University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bio-three — Competitive Intelligence Brief. https://druglandscape.com/ci/bio-three. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab